ArticleFrontiers in public health2025
Temporal trends and future projections of cysticercosis-induced epilepsy: insights from the global burden of disease study 2021- a cross-sectional study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Overcoming Cognitive Bias: A Case of Disseminated Neurocysticercosis in a Muslim Woman With Remote Pork Consumption.Clinical case reports · 2026Article
- Global, regional, and national burden and trends of idiopathic epilepsy among children and adolescents from 1990 to 2021: insights from the global burden of disease study 2021.Annals of medicine · 2025Article
- The burden and risk factors of chronic obstructive pulmonary disease in Asia and its countries from 1990 to 2021: a systematic analysis based on the 2021 global burden of disease study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The burden of disability and a significant portion of early deaths linked to Cysticercosis are primarily due to epilepsy. This research sought to clarify the temporal patterns and forecast the future prevalence and years lived with disability (YLDs) associated with Cysticercosis-induced epilepsy (CIE), providing crucial information for the development of targeted prevention and treatment strategies. Methods: Data from the 2021 Global Health database were used to measure the global, regional, and national burden of CIE by country, region, age, gender, and sociodemographic index (SDI). Age-period-cohort mode, the Auto Regressive Integrated Moving Average (ARIMA) model, and joinpoint regression analysis were also carried out. Results: The global prevalence and YLDs cases of CIE increased from 1992 to 2021, marking a 36.1 and 13.9% increase. However, the global prevalence and YLDs rates of CIE declined from 1992 to 2021, with estimated annual percentage change (EAPC) of -1.281 (95% CI: -1.373 to -1.19) and -1.878 (95% CI: -1.961 to -1.794). The age effect across global and SDI regions demonstrates an upward trend with advancing age, while unfavorable period effects are evident in high-SDI regions, where risk ratios for prevalence and YLDs exceed 1. The ARIMA model predicts a global rise in the total number of prevalence and YLDs cases from 2021 to 2036, with estimates reaching 4,955,416 (95% UI: 4,739,974 to 5,170,858) for prevalence and 2,032,208 (95% UI: 1,408,920 to 2,655,495) for YLDs by 2036. Conclusion: This study elucidates the complex epidemiological landscape of CIE, noting a global increase in prevalence and YLDs number against a decline in rates. Over the next 15 years, the burden of CIE is expected to remain significant, with high SDI regions warranting particular focus. The findings emphasize the necessity for region-specific strategies to mitigate the projected growth of CIE, highlighting the importance of tailored interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.